|
 
| |
來源：http://www.merckmillipore.com/TW/zh/20151117_174251?ReferrerURL=https%3A%2F%2Fwww.google.com.tw%2F
News Release
November 18, 2015
Markus Talanow: +49 6151 72-7144
Investor Relations: +49 6151 72-3321
Merck Completes Sigma-Aldrich Acquisition
-
$ 17 billion acquisition establishes leading player in life
science industry
-
New entity to enhance product range, capabilities and geographic reach
-
Customers benefit from a more than 300,000-product offering with
highly-respected brands distributed through leading life science e-commerce
and distribution platform
-
Organizational structure and senior management team in place
Darmstadt, Germany, November 18, 2015
—
Merck, a leading science and technology company, today announced the
completion of its $ 17 billion acquisition of Sigma-Aldrich, creating one of the
leaders in the $ 130 billion global industry to help solve the toughest problems
in life science.
The completion follows last week’s approval from the European
Commission, which was the final antitrust condition required to close the
Sigma-Aldrich transaction. Following the acquisition, Merck will have around
50,000 employees in 67 countries, working at 72 manufacturing sites worldwide.
Combined pro forma full-year life science sales amounted to �� 4.6 billion in
2014. As announced on publication of the results for the third quarter of 2015
on November 12, Merck expects sales to amount to between �� 12.6 billion and
�� 12.8 billion in 2015.
“The acquisition of Sigma-Aldrich marks the culmination of almost
a decade of transformation, further affirming that Merck is a leading science
and technology company,” said Karl-Ludwig Kley, CEO and Chairman of Merck.
“We’re now a leading player in the $ 130 billion global life science industry
and together with our two other growth platforms Healthcare and Performance
Materials, Merck is set to tackle global challenges that will fundamentally
change the world in which we live.”
Merck has made acquisitions and divestments totalling �� 38
billion in the past decade, turning the former pharma and chemicals company into
a science and technology company with three businesses in healthcare, life
science and performance materials that serve as platforms to compete in their
markets and drive innovations in these industries.
With the acquisition of Sigma-Aldrich, Merck will be able to
serve life science customers around the world with a highly attractive set of
established brands such as SAFC and BioReliance, in addition to Millipore and
Milli-Q, as well as an efficient supply chain that can support the delivery of
more than 300,000 products. The company will cover every step of the biotech
production chain, creating a complete end-to-end workflow with enhanced customer
service, a simplified customer interface and a leading distribution platform.
“This is a significant milestone in Merck’s long-term strategy to
invest in life science,” said Bernd Reckmann, Member of the Executive Board in
charge of Merck’s Life Science and Performance Materials business sectors. “The
acquisition of Millipore in 2010 was the first major step in that journey and
with the completion of the Sigma-Aldrich acquisition, we will take a quantum
leap toward securing our competitive position in that space.”
To ensure a smooth integration, Merck has made significant
progress on integration planning for the new business, which will be named Merck
all across the world, except for the U.S. and Canada, where the business will be
named MilliporeSigma. The future organization will tap into the industry-leading
talent of both legacy organizations, with a focus on promoting customer
centricity, continuous innovation and strengthened capabilities.
“With the acquisition complete, we can now start tackling the
challenge of solving the toughest problems in life science by collaborating with
the global scientific community and helping to increase access to healthcare. We
are excited to begin leveraging the proven operational excellence of our
organizations to provide a growing customer base with more efficient and
innovative solutions,” said Udit Batra, President and CEO of the life science
business of Merck. “We’ve designed the new organization to fully tap into our
combined capabilities, particularly in integrated supply chain operations,
information technology and e-commerce.”
Merck has created Strategic Marketing & Innovation teams (SMIs)
to promote and deliver innovation tailored to its life science customers’ needs.
Organized around three customer segments, these teams will be responsible for
defining customer segment strategy, product portfolio and roadmap and product
value propositions. The new business has Commercial Areas which are managed by
geography to leverage regional and local expertise. The Commercial Areas are
responsible for marketing, sales as well as customer and dealer relationships.
Sigma-Aldrich’s SAFC Commercial business, excluding the SAFC
Hitech business, will be part of Merck’s Life Science business sector. The SAFC
Hitech business will be integrated into Merck’s Performance Materials business
and will operate as part of its Integrated Circuits business unit. SAFC Hitech
and Merck’s Performance Materials businesses offer complementary technologies,
making these two businesses a natural fit.
About Merck
Merck is a leading science and technology company in healthcare, life science
and performance materials. About 50,000 employees, around the globe, work to
further develop technologies that improve and enhance life – from
biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge
systems for scientific research and production, to liquid crystals for
smartphones and LCD televisions. In 2014, Merck generated sales of �� 11.3
billion in 66 countries. Following the acquisition of Sigma-Aldrich, Merck
operates in 67 countries. Founded in 1668, Merck is the world's oldest
pharmaceutical and chemical company. The founding family remains the majority
owner of the publicly listed corporate group. Merck, Darmstadt, Germany holds
the global rights to the Merck name and brand. The only exceptions are the
United States and Canada, where the company operates as EMD Serono,
MilliporeSigma and EMD Performance Materials. For more information, please visit
www.merckgroup.com
|
